To assess whether this approach could be adapted to the repeated, sequential monitoring of individual animals, specifically under conditions of a partial loss of beta cells such as is expected in type 2 diabetic patients [31], we developed a new, dual modality nanoparticle probe that targets the GLP-1r and that is suitable for both fluorescence and MRI. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.